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Purpose: To evaluate the efficacy and safety of pregabalin (150 or 300 mg/d) as an adjunctive 
therapy for the treatment of postoperative pain.
Patients and methods: This study reports findings from three separate, multicenter, 
randomized, double-blind, placebo-controlled trials of adjunctive pregabalin for the treatment 
of postoperative pain. Patients underwent one of three categories of surgical procedures (one 
procedure per study): elective inguinal hernia repair (post-IHR); elective total knee arthroplasty 
(post-TKA); or total abdominal hysterectomy (posthysterectomy). The primary endpoint in each 
trial, mean worst pain over the past 24 hours, was assessed 24 hours post-IHR and posthyster-
ectomy, and 48 hours post-TKA. Patients rated their pain on a scale from 0 to 10, with higher 
scores indicating greater pain severity.
Results: In total, 425 (post-IHR), 307 (post-TKA), and 501 (posthysterectomy) patients 
were randomized to treatment. There were no statistically significant differences between 
the pregabalin and placebo groups with respect to the primary endpoint in any of the three 
trials. The least squares mean difference in worst pain, between 300 mg/d pregabalin and 
placebo, was -0.7 (95% confidence interval [CI] =-1.4, -0.1; Hochberg adjusted P=0.067) 
post-IHR; -0.34 (95% CI =-1.07, 0.39; P=0.362) post-TKA; and -0.2 (95% CI =-0.66, 0.31; 
P=0.471) posthysterectomy.
Conclusion: There were no significant differences between pregabalin and placebo with respect 
to the primary pain intensity measure in each of the three clinical trials. These studies encompass 
a large dataset (1,233 patients in total), and their results should be considered when assessing 
pregabalin’s effectiveness in postoperative pain. Further studies are required to determine the 
potential pain-reducing benefit of pregabalin in the postoperative setting.
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Introduction
Pregabalin is an α
2
δ ligand that modulates the activity of voltage-gated calcium 
channels. In the US, pregabalin is indicated for the treatment of neuropathic pain 
associated with diabetic peripheral neuropathy, with spinal cord injury, postherpetic 
neuralgia, fibromyalgia, and as an adjunctive therapy for adult patients with partial 
onset seizures.1 In the European Union, pregabalin is indicated for peripheral and 
central neuropathic pain, epilepsy, and generalized anxiety disorder.2
There are several positive reports for α
2
δ compounds, including pregabalin, for 
the management of postoperative pain in a variety of surgical models.3–9 However, 
these studies were conducted at single investigational sites and, often, assessed 
pregabalin in combination with other nonopioid analgesics. Additionally, there have 
Journal of Pain Research 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
10
singla et al
been reports of negative outcomes in postoperative trials 
with pregabalin, and the overall benefit of pregabalin in this 
setting is unclear.10–12
To further examine the safety and efficacy of pregabalin 
in the postoperative setting, three separate, large, multicenter, 
randomized, placebo-controlled trials of pregabalin as an 
adjunctive treatment for postoperative pain were conducted 
in patients following inguinal hernia repair (post-IHR), 
following total knee arthroplasty (post-TKA), or following 
hysterectomy (posthysterectomy). Here we report, for the 
first time, findings from these three trials.
Although the primary endpoint in each of these trials 
was not met, results from each trial are reported herein 
in order to contribute to a more balanced, evidence-based 
assessment of the efficacy of pregabalin for the treatment of 
postoperative pain.
Patients and methods
Each of the three trials was a multicenter, randomized, double-
blind, placebo-controlled study. All protocols adhered to the 
International Conference on Harmonization Good Clinical 
Practice Guidelines and were reviewed and approved by 
Institutional Review Boards at participating sites. All patients 
provided written informed consent prior to participation.
In all three trials, investigators used the sponsor’s inter-
active response technology system (via phone or Internet) 
to screen, randomize, and assign treatment to patients in a 
double-blinded manner. Pregabalin and placebo were admin-
istered as gray capsules identical in appearance. Patients 
were assigned a subject identification number at screening 
and a separate number at randomization to identify which 
treatment was to be received.
Post-ihR trial
Patients
The post-IHR trial was conducted at 34 sites in Australia, 
Canada, India, Spain, Sweden, and the US between January 
2008 and September 2009 (NCT00551135). Patients were 
males aged 18–75 years undergoing primary, elective, open, 
unilateral inguinal herniorrhaphy using Lichtenstein mesh 
repair under general anesthesia. Patients with emergency sur-
gery, hernia incarceration, and those undergoing additional 
procedures at the time of the total inguinal herniorrhaphy 
were excluded.
Treatment
Patients were randomized via a computer-generated 1:1:1:1 
ratio to one of four arms: oral pregabalin 50 mg/d (25 mg 
twice daily [bid]), 150 mg/d (75 mg bid), or 300 mg/d 
(150 mg bid); or placebo (bid). Patients received two pre-
operative treatment doses at 12 hours and 2 hours before 
surgery and continued treatment (bid dosing) for 1 week 
post-IHR (Figure 1). Details of rescue medications allowed 
are shown in Table 1.
Efficacy outcome measures
The primary efficacy measure was mean worst pain over the 
past 24 hours, assessed 24 hours post-IHR. Patients rated 
their pain using the modified Brief Pain Inventory-short form 
(mBPI-sf) numeric rating scale (NRS) from 0= no pain to 
10= pain as bad as you can imagine.
Secondary measures of pain included worst, average, 
and current pain intensity assessed 72 hours post-IHR and 
severity of movement-induced pain (sitting, walking, or 
coughing) assessed at 1, 2, and 48 hours post-IHR. Continued 
pain in the area of surgery was assessed by telephone at 1, 
3, and 6 months post-IHR. Patients who reported continued 
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Figure 1 Design of the three clinical trials.
Abbreviations: bid, twice daily; ihR, inguinal hernia repair; TKa, total knee 
arthroplasty.
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pain were asked to complete the Neuropathic Pain Symptom 
Inventory (NSPI) questionnaire.13
The total cumulative dose and total daily dose of opioids, 
calculated as mg of oral morphine equivalent, were determined 
and included post-IHR opioids administered by any route.
safety measures
Adverse events (AEs), safety, tolerability, and prespeci-
fied wound complications were evaluated and monitored 
throughout the trial.
statistical analysis
A sample size of 100 patients per group was calculated to 
provide 90% power (two-sided α=0.05) to detect a treatment 
effect of 1.0 on the pain NRS, assuming a standard devia-
tion (SD) of 2.2. Efficacy analyses were carried out in the 
modified intent-to-treat population, defined as all randomized 
patients who were administered presurgery medications, had 
no surgical or anesthetic complications, and for whom at least 
one postbaseline safety evaluation was obtained. The primary 
endpoint analyses were conducted using analysis of variance 
with treatment and center included in the models and utilized 
Hochberg’s multiple comparisons adjustment.
Safety analyses were conducted on all randomized 
patients who received at least one dose of study medication 
using descriptive statistics.
Post-TKa trial
Patients
The post-TKA trial was conducted at 24 sites in the US 
between May 2007 and December 2008 (NCT00442546). 
Patients were males and females aged 18–80 years with 
osteoarthritis undergoing elective TKA. Patients undergo-
ing revision, unicompartmental, or bilateral TKA, or who 
had a planned second TKA at the time of the elective TKA 
procedure were excluded. Choice of anesthesia (spinal or 
epidural anesthesia) was determined by the individual stan-
dard of care at each center.
Treatment
Patients were randomized via a computer-generated 
1:1:1 ratio to one of three arms: oral pregabalin 150 mg/d 
Table 1 Details of permitted preoperative, intraoperative, and postoperative anesthesia and analgesia techniques
Preoperative Intraoperative Postoperative
Post-ihR Premedication immediately  
prior to surgery included  
midazolam or temazepam, as  
needed. Patients could  
receive propofol for  
induction and sevoflurane,  
isoflurane, or desflurane. 
intraoperative analgesia was  
managed with fentanyl or  
sufentanil, as needed. Muscle  
relaxants were allowed during  
the surgical procedure.
Local infiltration of the surgical site at the end of surgery 
was specified as 20–30 ml (beneath external oblique 
fascia) of 0.5% bupivacaine. standard analgesic medication 
consisted of 500 mg naproxen (bid) for  
3 days and then as needed. if inadequate, a combination 
of 50 mg tramadol and 500–650 mg acetaminophen was 
administered every 4 hours, as needed. if still inadequate, 
5 mg oxycodone and 500–650 mg acetaminophen was 
administered every 4 hours, as needed.
Post-TKa sedation with midazolam  
(0.05 mg/kg titrated to effect)  
or propofol (25–75 µg/kg/h)  
infusion. Use of Pca/Pcea  
to maintain pain at rest at  
4 on the 11-point nRs. 
sedation with midazolam  
(0.05 mg/kg titrated to effect) or  
propofol (25–75 µg/kg/h) infusion. 
anesthesia during the TKa was  
provided by epidural, spinal,  
or combined spinal/epidural  
analgesia with local anesthetic  
and hydromorphone or fentanyl.
Use of peripheral nerve block was allowed for the first  
36 hours postsurgery. Patients then switched to oral analgesia 
5 mg hydrocodone bitartrate/500 mg acetaminophen tablets 
every 4–6 hours as needed; or oxycodone/acetaminophen 
(up to the maximum dose) and/or intravenous opioid Pca 
(morphine, hydromorphone, fentanyl) depending on the site’s 
standard care. Pca/Pcea was used to maintain pain at rest 
at 4 on the 11-point nRs. after discontinuation of the 
epidural, oral warfarin, or low molecular weight heparin was 
used to avoid deep venous thrombosis prophylaxis.
Posthysterectomy general anesthesia supplemental analgesia medication  
consisted of parenteral morphine  
(or similar opioid agent) by  
Pca pump, which was available  
immediately after surgery. For  
analgesia during the period before  
Pca was started, opioid analgesic  
was given by bolus injections.
Parenteral morphine (or similar opioid analgesic agent) 
was administered by Pca, as soon as possible postsurgery. 
Opioid analgesics were also administered by bolus 
injection, if required. If insufficient, additional opioid 
analgesia was administered by bolus injection. if opioid 
analgesia was inadequate or not well tolerated during 
the period when Pca was used, nsaiD (naproxen, 
ibuprofen, diclofenac, ketorolac, or ketoprofen) and/or 
acetaminophen was added or substituted as appropriate.
Abbreviations: bid, twice daily; IHR, inguinal hernia repair; NRS, numerical rated scale; NSAID, nonsteroidal anti-inflammatory drug; PCA, patient-controlled analgesia; 
Pcea, patient-controlled epidural analgesia; TKa, total knee arthroplasty.
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(75 mg bid) or 300 mg/d (150 mg bid), or placebo (bid). 
Patients received two preoperative treatment doses at 
12 hours and 2 hours before surgery and continued treatment 
(bid dosing) for 6 weeks post-TKA (Figure 1). Details of 
rescue medications allowed are shown in Table 1.
Efficacy outcome measures
The primary efficacy measure was mean worst pain over the 
past 24 hours, assessed 48 hours post-TKA using the pain 
NRS from the mBPI-sf.
Secondary measures of pain included worst, average, and 
current pain intensity assessed 72 hours post-TKA. Passive and 
active flexion range of motion (ROM) of the operated knee 
were measured at baseline, and at weeks 2, 4, and 6 (or early 
termination) post-TKA. Continued pain in the area of surgery 
was assessed by telephone at 3 and 6 months post-TKA.
The total cumulative dose and total daily dose of opi-
oids, calculated as mg of oral morphine equivalent, were 
determined and included post-TKA opioids administered 
by any route.
safety measures
AEs, safety, tolerability, and prespecified wound complica-
tions were evaluated and monitored throughout the trial.
statistical analysis
A sample size of 100 patients per group was calculated to 
provide 90% power (two-sided α=0.05) to detect a treatment 
effect of 1.0 on the pain NRS, assuming a standard deviation 
(SD) of 2.2. Efficacy analyses were carried out in the modified 
intent-to-treat population, defined as all randomized patients 
who were administered presurgery medications, had no surgical 
or anesthetic complications, and for whom at least one post-
baseline safety evaluation was obtained. The primary endpoint 
analyses were conducted using analysis of variance with treat-
ment and center included in the models. As a result of prespeci-
fied interim analyses, the trial was terminated early owing to 
the primary outcome measure (mean pain over the previous 
24 hours, assessed 48 hours post-TKA) not being significantly 
improved with pregabalin as compared with placebo.
Safety analyses were conducted on all randomized 
patients who received at least one dose of study medication 
using descriptive statistics.
Posthysterectomy trial
Patients
The posthysterectomy trial was conducted at 37 sites in 
Canada, the Czech Republic, Hong Kong, South Africa, 
Spain, Sweden, Thailand, the UK, and the US between June 
2007 and October 2010 (NCT00468845). Patients were 
females aged 25–70 years undergoing elective abdominal 
hysterectomy using a transverse incision with or without 
bilateral salpingo-oophorectomy under general anesthesia. 
Patients having vaginal hysterectomy or additional proce-
dures to the abdominal hysterectomy (such as those involv-
ing the bladder) were excluded. Use of wound infiltration 
using local anesthetics was not controlled across the study 
centers.
Treatment
Patients in the posthysterectomy trial were randomized via 
a computer-generated 1:1:1 ratio to one of three arms: oral 
pregabalin 150 mg/d (75 mg bid) or 300 mg/d (150 mg 
bid), or placebo (bid). Patients received two preoperative 
treatment doses at 12 hours and 2 hours before surgery and 
continued treatment (bid dosing) for 4 weeks postsurgery 
(Figure 1). Details of rescue medications allowed are shown 
in Table 1.
Efficacy outcome measures
The primary efficacy measure was mean worst pain over the 
past 24 hours, assessed 24 hours posthysterectomy using the 
pain NRS from the mBPI-sf.
Secondary measures of pain included worst and current 
pain intensity assessed 72 hours posthysterectomy and sever-
ity of movement-related pain (sitting and forced expiration) 
assessed up to 72 hours postsurgery. Continued pain in the 
area of surgery was assessed by telephone at 3 and 6 months 
posthysterectomy.
The total cumulative dose and total daily dose of opi-
oids, calculated as mg of oral morphine equivalent, were 
determined and included post-TKA opioids administered 
by any route.
safety measures
AEs, safety, tolerability, and prespecified wound complica-
tions were evaluated and monitored throughout the trial.
statistical analysis
A sample size of 100 patients per group was calculated to 
provide 90% power (two-sided α=0.05) to detect a treat-
ment effect of 1.0 on the pain NRS, assuming a standard 
deviation (SD) of 2.2. Efficacy analyses were carried out 
in the modified intent-to-treat population, defined as all 
randomized patients who were administered presurgery 
medications, had no surgical or anesthetic complications, 
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and for whom at least one postbaseline safety evaluation was 
obtained. The primary endpoint analyses were conducted 
using analysis of variance with treatment and center included 
in the models and a salpingo-oophorectomy stratification of 
the data. In addition, a weighted z-score test14 was used to 
compare the pregabalin and placebo groups for the primary 
efficacy endpoint, using the following weights: square root 
(137/300) for prior-to-interim data and square root (163/300) 
for postinterim data.
Safety analyses were conducted on all randomized 
patients who received at least one dose of study medication 
using descriptive statistics.
Results
Post-ihR trial
Patients
In total, 425 patients were randomized to treatment, and 
approximately 96% of these patients completed treatment 
(Figure 2). Patient demographics were similar between treat-
ment groups (Table 2).
Primary endpoint
There was no difference between pregabalin and placebo 
treatment groups with respect to the primary endpoint of 
mean worst pain score over the past 24 hours, assessed 
at 24 hours post-IHR. The least squares mean difference 
between 300 mg/d pregabalin and placebo was -0.7 
(95% confidence interval [CI] =-1.4, -0.1; P=0.033; 
Hochberg adjusted P=0.067).
secondary endpoints
Pain
There was no difference between the pregabalin and placebo 
treatment groups for any measure of pain intensity (worst 
pain, average pain, current pain) at 72 hours post-IHR 
(Table 3). Continued pain in the area of surgery at 1 month 
post-IHR was reported by 20, 24, and 19 patients in the 50, 
150, and 300 mg/d pregabalin groups, respectively, versus 
26 patients in the placebo group. Patients who reported 
continued pain were asked to complete the NSPI.13 Mean 
(SD) total NSPI scores were similar between the pregaba-
lin groups (50 mg/d =0.03 [0.03]; 150 mg/d =0.03 [0.05]; 
300 mg/d =0.05 [0.04]) and the placebo group (0.04 [0.04]). 
Fewer patients reported continued pain at 3 months post-IHR, 
and by 6 months post-IHR, only 1 participant in each of the 
pregabalin groups reported continued pain compared with 0 
in the placebo group.
Patients reported less movement-related pain (caused 
by sitting, walking, or coughing) at 1 hour post-IHR with 
300 mg/d pregabalin, but not with 50 or 150 mg/d pregaba-
lin, compared with placebo (Figure 3). Most movement-
related pain outcomes at 2 and 48 hours post-IHR were not 
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Figure 2 Participant disposition.
Abbreviations: AE, adverse event; GCP, good clinical practice; IHR, inguinal hernia repair; MITT, modified intent-to-treat population; PGB, pregabalin; TKA, total knee 
arthroplasty.
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Pregabalin for postoperative pain
significantly different with pregabalin, including 300 mg/d, 
compared with placebo.
Opioid use
The total cumulative opioid requirement at 24 hours post-IHR 
was decreased by 41% (P=0.035) and by 59% (P=0.002) in 
patients receiving 150 and 300 mg/d pregabalin, respectively, 
compared with placebo (Table 4). Cumulative opioid use 
was lower for the pregabalin 300 mg/d group compared with 
placebo for each of the first 7 days post-IHR (all P,0.05).
adverse events
Treatment-emergent AEs (all-causality) occurring in $10% 
of any treatment group are summarized in Table 5. The most 
frequently reported AEs across all treatment groups were 
constipation, nausea, fatigue, dizziness, and somnolence. The 
majority of all AEs were mild to moderate in intensity.
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Post-TKa trial
Patients
In total, 307 patients were randomized to treatment, and 
approximately 69% of these patients completed treatment 
(Figure 2). Patient demographics were similar between treat-
ment groups (Table 2).
Primary endpoint
There was no difference between the pregabalin and pla-
cebo treatment groups with respect to the primary endpoint 
of mean worst pain score over the past 24 hours, assessed 
at 48 hours post-TKA. The least squares mean difference 
between 300 mg/d pregabalin and placebo was -0.34 
(95% CI =-1.07, 0.39; P=0.362).
secondary endpoints
Pain
There was no difference between the pregabalin and placebo 
treatment groups for any measure of pain intensity (worst pain, 
average pain, current pain) at 72 hours post-TKA (Table 3). 
The incidence of persistent pain at 3 months (300 mg/d 
pregabalin =22/59 [37%]; placebo =27/61 [44%]) and at 
6 months (300 mg/d pregabalin =15/62 [24%]; placebo =14/61 
[23%]) post-TKA was similar between treatment groups, 
though only two-thirds of patients in each group were assessed 
owing to early termination of the trial. The rate of early ter-
mination of patients did not differ between groups.
Passive ROM for the operated knee was greater for 
the 300 mg/d pregabalin group compared with placebo 
at 24 hours (difference from placebo =6.532°; P=0.015), 
72 hours (difference =7.135°; P=0.006), 96 hours 
(difference =11.173°; P=0.008), and 120 hours (differ-
ence =17.941°; P=0.004; Figure 4) post-TKA. There was 
also a significant difference from placebo at discharge 
(difference =4.407°; P=0.022) and at week 4 post-TKA 
(difference =5.771°; P=0.018; Figure 4). Passive ROM 
at most prespecified time points did not significantly dif-
fer between 150 mg/d pregabalin and placebo at most 
time points. Active ROM (upon flexion) was significantly 
greater in the 300 mg/d pregabalin group compared with 
placebo only at week 4 (difference =5.32°; 95% CI =0.20, 
10.43; P=0.042). At week 6, all treatment groups had least 
squares (LS) mean ROM .90° on passive flexion (LS mean 
standard error [SE]: 150 mg/d pregabalin =110.32° [1.63]; 
300 mg/d pregabalin =111.35° [1.88]; placebo =108.94° 
[1.85]) and on active flexion (LS mean [SE]: 150 mg/d 
pregabalin =105.35° [1.85]; 300 mg/d pregabalin =106.25° 
[2.14]; placebo =103.98° [2.05]).Ta
bl
e 
5 
M
os
t 
co
m
m
on
 t
re
at
m
en
t-
em
er
ge
nt
 a
dv
er
se
 e
ve
nt
s 
(n
 [
%
], 
al
l-c
au
sa
lit
y)
 in
 a
ny
 t
re
at
m
en
t 
gr
ou
p 
in
 a
ny
 t
ri
al
E
ve
nt
s 
oc
cu
rr
in
g 
 
in
 $
10
%
 o
f a
ny
  
tr
ea
tm
en
t 
gr
ou
p
P
os
t-
IH
R
P
os
t-
T
K
A
P
os
th
ys
te
re
ct
om
y
P
re
ga
ba
lin
P
la
ce
bo
P
re
ga
ba
lin
P
la
ce
bo
P
re
ga
ba
lin
P
la
ce
bo
50
 m
g/
d
15
0 
m
g/
d
30
0 
m
g/
d
15
0 
m
g/
d
30
0 
m
g/
d
15
0 
m
g/
d
30
0 
m
g/
d
n=
10
8
n=
10
6
n=
10
3
n=
10
8
n=
98
n=
96
n=
98
n=
16
1
n=
16
6
n=
16
7
c
on
st
ip
at
io
n
21
 (
19
.4
)
22
 (
20
.8
)
27
 (
26
.2
)
27
 (
25
.0
)
24
 (
24
.5
)
12
 (
12
.5
)
30
 (
30
.6
)
46
 (
28
.6
)
49
 (
29
.5
)
46
 (
27
.5
)
n
au
se
a
21
 (
19
.4
)
18
 (
17
.0
)
14
 (
13
.6
)
22
 (
20
.4
)
29
 (
29
.6
)
31
 (
32
.3
)
51
 (
52
.0
)
67
 (
41
.6
)
60
 (
36
.1
)
76
 (
45
.5
)
Fa
tig
ue
24
 (
22
.2
)
18
 (
17
.0
)
23
 (
22
.3
)
23
 (
21
.3
)
20
 (
20
.4
)
15
 (
15
.6
)
19
 (
19
.4
)
38
 (
23
.6
)
46
 (
27
.7
)
34
 (
20
.4
)
D
iz
zi
ne
ss
15
 (
13
.9
)
20
 (
18
.9
)
29
 (
28
.2
)
16
 (
14
.8
)
20
 (
20
.4
)
25
 (
26
.0
)
16
 (
16
.3
)
51
 (
31
.7
)
52
 (
31
.3
)
37
 (
22
.2
)
so
m
no
le
nc
e
24
 (
22
.2
)
25
 (
23
.6
)
25
 (
24
.3
)
28
 (
25
.9
)
24
 (
24
.5
)
22
 (
22
.9
)
20
 (
20
.4
)
39
 (
24
.2
)
39
 (
23
.5
)
36
 (
21
.6
)
h
ea
da
ch
e
5 
(4
.6
)
3 
(2
.8
)
1 
(1
.0
)
3 
(2
.8
)
7 
(7
.1
)
3 
(3
.1
)
9 
(9
.2
)
27
 (
16
.8
)
23
 (
13
.9
)
19
 (
11
.4
)
V
om
iti
ng
2 
(1
.9
)
7 
(6
.6
)
1 
(1
.0
)
7 
(6
.5
)
14
 (
14
.3
)
15
 (
15
.6
)
25
 (
25
.5
)
33
 (
20
.5
)
20
 (
12
.0
)
30
 (
18
.0
)
Py
re
xi
a
1 
(0
.9
)
0 
(0
)
1 
(1
.0
)
4 
(3
.7
)
14
 (
14
.3
)
16
 (
16
.7
)
5 
(5
.1
)
32
 (
19
.9
)
29
 (
17
.5
)
25
 (
15
.0
)
in
so
m
ni
a
1 
(0
.9
)
0 
(0
)
3 
(2
.9
)
3 
(2
.8
)
8 
(8
.2
)
12
 (
12
.5
)
17
 (
17
.3
)
9 
(5
.6
)
9 
(5
.4
)
10
 (
6.
0)
Pr
ur
itu
s
9 
(8
.3
)
7 
(6
.6
)
4 
(3
.9
)
6 
(5
.6
)
15
 (
15
.3
)
12
 (
12
.5
)
21
 (
21
.4
)
27
 (
16
.8
)
22
 (
13
.3
)
26
 (
15
.6
)
h
yp
ot
en
si
on
7 
(6
.5
)
3 
(2
.8
)
4 
(3
.9
)
2 
(1
.9
)
13
 (
13
.3
)
12
 (
12
.5
)
5 
(5
.1
)
2 
(1
.2
)
3 
(1
.8
)
1 
(0
.6
)
D
is
tu
rb
an
ce
 in
 a
tt
en
tio
n
11
 (
10
.2
)
11
 (
10
.4
)
15
 (
14
.6
)
16
 (
14
.8
)
10
 (
10
.2
)
11
 (
11
.5
)
11
 (
11
.2
)
24
 (
14
.9
)
30
 (
18
.1
)
23
 (
13
.8
)
D
ys
ur
ia
10
 (
9.
3)
6 
(5
.7
)
10
 (
9.
7)
10
 (
9.
3)
5 
(5
.1
)
4 
(4
.2
)
5 
(5
.1
)
14
 (
8.
7)
22
 (
13
.3
)
17
 (
10
.2
)
c
on
fu
si
on
al
 s
ta
te
6 
(5
.6
)
3 
(2
.8
)
8 
(7
.8
)
6 
(5
.6
)
9 
(9
.2
)
10
 (
10
.4
)
5 
(5
.1
)
12
 (
7.
5)
12
 (
7.
2)
9 
(5
.4
)
Pe
ri
ph
er
al
 e
de
m
a
0 
(0
)
0 
(0
)
0 
(0
)
1 
(0
.9
)
8 
(8
.2
)
9 
(9
.4
)
11
 (
11
.2
)
4 
(2
.5
)
1 
(0
.6
)
1 
(0
.6
)
A
bb
re
vi
at
io
ns
: i
h
R
, i
ng
ui
na
l h
er
ni
a 
re
pa
ir
; T
K
a
, t
ot
al
 k
ne
e 
ar
th
ro
pl
as
ty
.
Journal of Pain Research 2015:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
17
Pregabalin for postoperative pain
Opioid use
The cumulative opioid requirement at 48 hours post-TKA 
was reduced by 30% (P=0.028) and by 25% (P=0.082) for the 
150 and 300 mg/d pregabalin groups, respectively, compared 
with placebo (Table 4).
adverse events
Treatment-emergent AEs (all-causality) occurring in $10% 
of any treatment group are summarized in Table 5. The most 
frequently reported AEs across all treatment groups were con-
stipation, nausea, fatigue, dizziness, somnolence, and vomiting. 
The majority of all AEs were mild to moderate in intensity.
Posthysterectomy trial
Patients
In total, 501 patients were randomized to treatment, and 
approximately 83% of these patients completed treatment 
(Figure 2). Patient demographics were similar between treat-
ment groups (Table 2). Overall, 89%, 95%, and 92% of patients 
were premenopausal in the 150 mg/d pregabalin, 300 mg/d 
pregabalin, and placebo treatment groups, respectively.
Primary endpoint
There was no difference between the pregabalin and placebo 
treatment groups with respect to the primary endpoint of 
mean worst pain score over the past 24 hours, assessed at 
24 hours posthysterectomy. The least squares mean difference 
between 300 mg/d pregabalin and placebo was -0.2 (95% CI 
=-0.66, 0.31; weighted z-score =-0.721; P=0.471).
secondary endpoints
Pain
There was no significant difference between the pregabalin 
and placebo treatment groups for most measures of pain 
intensity (worst pain, average pain, current pain) at 72 hours 
posthysterectomy (Table 3). Likewise, there were no signifi-
cant differences in the incidence of chronic pain at 3 months 
(300 mg/d pregabalin =22/126 [18%]; placebo =14/137 
[10%]) or at 6 months (300 mg/d pregabalin =8/126 [6%]; 
placebo =6/138 [4%]) posthysterectomy.
There was no signif icant difference between the 
pregabalin and placebo treatment groups in movement-
related pain caused by sitting or by forced expiration up to 
72 hours posthysterectomy (data not shown).
Opioid use
The cumulative total opioid requirement, in mg-based 
morphine equivalents, was significantly lower for 150 
mg/d pregabalin compared with placebo at discharge (LS 
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Figure 4 Passive range of motion of the operated knee post-TKa.
Notes: Pregabalin 150 mg/d vs placebo; P,0.05 at 120 hours post-TKa. Pregabalin 300 mg/d vs placebo; P,0.01 at 72, 96, and 120 hours post-TKa. P,0.05 at 24 hours, 
at discharge, and at Week 4 post-TKa.
Abbreviations: ls, least squares; TKa, total knee arthroscopy.
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mean difference =-31.04 [15.05] mg; P=0.040), but not for 
pregabalin 300 mg/d versus placebo (Table 4).
adverse events
Treatment-emergent AEs (all-causality) occurring in $10% 
of any treatment group are summarized in Table 5. The most 
frequently reported AEs across all treatment groups were 
constipation, nausea, fatigue, dizziness, and somnolence. The 
majority of all AEs were mild to moderate in intensity.
Discussion
In each of the three trials presented here, there was no sig-
nificant difference between pregabalin and placebo with 
respect to the primary endpoint of mean worst pain after 
surgery (at 24 hours post-IHR and posthysterectomy, and at 
48 hours post-TKA). Many secondary measures of pain also 
failed to demonstrate efficacy of pregabalin compared with 
placebo. Minimal improvements over placebo in functional/
movement-related pain were evident with 300 mg/d pregaba-
lin in the post-IHR and post-TKA trials. There was also 
some evidence of an opioid-sparing effect with pregabalin 
in each trial, which is consistent with findings from a previ-
ous meta-analysis of pregabalin trials for the treatment of 
postoperative pain.15
The most frequently reported AEs with pregabalin in all 
three trials were nausea, dizziness, somnolence, constipation, 
and fatigue. The majority of AEs were mild to moderate in 
severity. Some AEs may be related to general and regional 
anesthesia (eg, dizziness, nausea, and vomiting), although 
dizziness was reported more frequently in pregabalin 
patients than in those receiving placebo across all three 
trials. Overall, the AEs reported here are consistent with 
those commonly reported in randomized controlled trials of 
pregabalin for other indications, and no new safety issues 
were identified.16
Previous clinical trials of α
2
δ ligands for postoperative 
pain, using surgical models similar to those presented here, 
have yielded mixed results. For example, a preoperative dose 
of 1,200 mg gabapentin was shown to reduce pain scores and 
opioid consumption posthysterectomy.17 Gabapentin has also 
been shown to reduce the intensity of acute pain and opioid 
use following IHR.18 Pregabalin has also demonstrated some 
efficacy for the treatment of postoperative pain. For example, 
perioperative administration of pregabalin, in conjunction with 
celecoxib, reduced opioid intake and decreased neuropathic 
pain scores at 3 and 6 months following TKA.5 Likewise, pre-
operative administration of 300 mg pregabalin reduced pain 
scores and opioid consumption following total, or subtotal, 
hysterectomy with or without salpingo-oophorectomy.7 In 
contrast, however, pre- and perioperative administration of 
pregabalin in conjunction with either paracetamol, or para-
cetamol and dexamethasone, did not reduce posthysterectomy 
pain levels or opioid consumption.11
The three studies presented here were each large, 
controlled, randomized trials with multiple pain-related 
endpoints. All three studies failed to meet their primary, 
prespecified efficacy endpoint. However, limitations related 
to the design of these trials should be taken into consideration. 
Specifically, the prespecified primary endpoint of worst 
pain over the past 24 hours may not be the most sensitive 
measure of postoperative pain. Patients were asked to recall 
worst pain at a point in time at which their pain may have 
been at its worst level, or may have receded, and current pain 
experience may have influenced their recall. Indeed, given 
the complex nature of the subjective experience of pain, the 
debate regarding valid and reliable measures of acute pain, 
particularly in the postoperative setting, is ongoing.19,20
Additionally, in all three studies, the anesthetic and 
postoperative analgesic techniques used at each investiga-
tional site were at the discretion of the physician. Table 1 
demonstrates the vast variability of preoperative, intraopera-
tive, and postoperative analgesics that each study protocol 
allowed. Analgesic adjuvants such as nonsteroidal anti-
inflammatory drugs and local anesthetics have significant 
efficacy against postoperative pain21,22 and may not have 
been used equally in the pregabalin and placebo groups in 
the three trials. Likewise, intraoperative anesthetic techniques 
(especially nerve blocks) can have a significant impact on 
the postoperative pain experience and may not have been 
equally distributed between treatment groups. Larger-scale 
multicenter clinical trials, such as the ones reported here, will 
inevitably incorporate such variations in surgical technique, 
anesthetic practice, perioperative pain management, and 
data collection techniques. Such variations may have acted 
as confounding factors in the primary efficacy analyses and 
may have contributed, at least in part, to a lack of treatment 
effect with pregabalin. It should be noted, however, that the 
variation present in each of the three studies more accurately 
represents real-world clinical practice compared with a highly 
controlled clinical trial that places restrictions on the use of 
anesthetic/surgical techniques.
Conclusion
There was no significant difference between pregabalin and 
placebo with respect to the primary endpoint (worst pain 24/48 
hours postsurgery) for any of the surgical models examined. 
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However, there was suggestive evidence of efficacy for other 
secondary endpoints, such as pain upon movement in the 
post-IHR trial and ROM in the post-TKA trial. There was 
also evidence of a pregabalin-mediated opioid-sparing effect 
in each trial. Overall, further controlled studies are needed 
to fully investigate the potential pain-reducing benefit of 
pregabalin in the postoperative setting.
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